Recent Winners On GuerillaStockTrading

Alert Price: $12.72
High Price: $23.75
Results: 87% in 20 Days
Alert Price: $27.22
High Price: $35.88
Results: 32% in 6 Days
Alert Price: $4.43
High Price: $5.45
Results: 23% in 3 Days
Alert Price: $8.30
High Price: $10.25
Results: 23% in 12 Days
Alert Price: $15.40
High Price: $18.67
Results: 21% in 11 Days
Alert Price: $6.89
High Price: $8.25
Results: 20% in 11 Days
Alert Price: $7.17
High Price: $8.24
Results: 15% in 6 Days
Alert Price: $8.49
High Price: $9.55
Results: 12% in 7 Days
Alert Price: $19.50
High Price: $21.93
Results: 12% in 26 Days
Alert Price: $20.00
High Price: $22.42
Results: 12% in 26 Days
Alert Price: $48.15
High Price: $52.90
Results: 10% in 14 Days
Alert Price: $67.61
High Price: $73.56
Results: 9% in 12 Days
Alert Price: $19.94
High Price: $20.75
Results: 4% in 13 Days
Alert Price: $31.53
High Price: $32.69
Results: 4% in 9 Days
Alert Price: $14.05
High Price: $14.55
Results: 4% in 21 Days

Past results are not indicative of future profits. This table is accurate, though not every trade is represented.

Top Catalysts For The Week Ending January 20 2017

Sanchez Energy = Eagleford Acquisition Doubles Drilling Inventory

Mobileye = Goldman Sachs Raised Mobileye To A Buy Rating

Tesla = Expanding Investment In Gigafactory by $350 Million, Adding 550 New Jobs To Make Model 3

AbbVie = Gets FDA Approval For Imbruvica

3D Systems = Hearing Takeover Rumors Circulating About GE

International Game Technology = Wins Big Contract From Svenska Spel in Sweden

WiLAN = Court of Appeals Grants WiLAN Positive Rulings In Case Against Ericsson

Gilead Sciences = Hearing Takeover Rumors Circulating

Juno = Hearing Juno Takeover Rumors Circulating

Fusion Telecommunications = Awarded 3-year $100K For Managed Cloud Services

Teva Pharmaceutical = Receives FDA Approval For Vantrela ER

EPAM Systems = Lands Giant UBS Multi-year Agreement Valued At Over $300 Million

Tutor Perini Building = Receives Notice of Intent To Award a $1.37 Billion Contract From Los Angeles County

Amicus Therapeutics = Hearing Takeover Rumors Circulating

CEMEX = Trump Build That Wall Play

Iridium Communications = Announces Successful First Launch For Space-Based ADS-B Network

Applied Optoelectronics = Play On Switch From Copper To Optical Interconnect Inside Datacenters

3D Systems = Expands its Virtual Surgical Planning Service to Include Cranial Applications

Trading Lessons

Mainstream Financial News


Teva Pharmaceutical Receives FDA Approval For Vantrela ER

Follow Us on StockTwits

January 18, 2017: U.S. Food and Drug Administration (FDA) approved Teva Pharmaceutical’s VANTRELATM ER (hydrocodone bitartrate) extended-release tablets [CII] formulated with Teva’s proprietary abuse deterrence technology. VANTRELA ER is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. The products approval is supported by a clinical program that evaluated the safety and efficacy of VANTRELA ER, as well as its abuse potential in laboratory-based in vitro manipulation and extraction studies, pharmacokinetic studies, and clinical abuse potential (CAP) studies.

January 9, 2017: Teva Pharmaceutical Industries CEO said, “…our migraine drug could create multiple billions in revenue.” The comment was made at the JP Morgan conference.

– Targeting 30% of the $8-12B migraine drug market

December 15, 2016: Teva Pharmaceutical Industries spokesperson says received complaint from state AGs regarding antitrust charges against generic drug makers; we are reviewing the complaint.

December 8, 2016: Teva Pharmaceutical Industries CEO said at a Citi conference that he expects 2017 to be a much better year for Teva.

December 7, 2016: Oversold Teva Pharmaceutical’s just got an Outperform rating from Oppenheimer.

December 5, 2016: Teva Pharmaceutical announced that it had received a positive outcome through the variation procedure to remove the pregnancy contraindication from the European label for COPAXONE(glatiramer acetate injection) 20 mg/mL. The product was originally authorized through a decentralized procedure in Europe.

The removal of the pregnancy contraindication follows a Positive Variation Assessment Report issued by the United Kingdom’s Medicines and Healthcare Products Regulatory Agency (MHRA; Reference Member State), and agreed by all Concerned Member States (CMS) in Europe, that were involved in the procedure. Granting of governmental approvals by all involved EU Member States will happen shortly. COPAXONEis indicated for the treatment of patients with relapsing forms of multiple sclerosis (RMS).

The removal of the contraindication is based on a comprehensive examination of available prospective pregnancy cases with known outcome and confirmed exposure to COPAXONE. A supporting analysis was also provided comparing data from Teva’s Glatiramer Acetate (GA) Pharmacovigilance Database which captured more than 8,000 pregnancies over a period of more than 20 years.

December 5, 2016: Teva Pharmaceutical announced that Dipankar Bhattacharjee had been appointed President and Chief Executive Officer, Global Generic Medicines Group, effective today. Mr. Bhattacharjee, who has served as President and CEO of Teva Generics Europe since April 2013, succeeds Sigurdur (Siggi) Olafsson, who will step down from his role and remain active with the Company until officially retiring at the end of the first quarter of 2017 to ensure an orderly transition. Mr. Bhattacharjee will be based in the U.S.

As President and CEO of Teva Generics Europe, Mr. Bhattacharjee has a proven track record of improving revenues and profitability, significantly increasing operating profit margins in the European generics business. Under his leadership, Tevas European business demonstrated consistent improvement in sales and profits, establishing Teva as one of the premier generics companies in Europe. He has focused on improving and enhancing the European generics operations, leading a full European integration of Actavis Generics and overseeing successful new product launches.

In conjunction with today’s announcement, Teva is reaffirming its full-year 2016 outlook. Revenues for the full year 2016 are expected to be $21.6-$21.9 billion and revenues for the fourth quarter of the year 2016 are projected to be $6.2-$6.5 billion. Non-GAAP EPS for 2016 is expected to be $5.10-$5.20, based on a weighted average number of shares of 1,020 million; non-GAAP EPS is projected to be $1.34-$1.44, based on a weighted average number of shares of 1,077 million. Cash flow from operating activities for 2016 is expected to be $4.8-$5.0 billion; cash flow from operating activities for the fourth quarter of 2016 is expected to be $1.0-$1.2 billion.

November 30, 2016: Hearing vague takeover chatter circulating about Teva. Teva has a market cap of $35 billion so it would be hard to keep a deal of that size quiet for long. It seems takeover rumors are always circulating. I can’t track down the source of the rumors, and so I’m skeptical about them for now. Will keep following the rumors and update you on any substantive information.

Teva Pharmaceutical Stock Chart

The Finviz screener settings used to find Teva Pharmaceutical’s are: Sector Healthcare, Forward P/E Under 10, EPS growth qtr over qtr Over 30%, Gross Margin High (>50%)

Teva Pharmaceutical Industries Ltd. is a leading global pharmaceutical company, committed to increasing access to high-quality healthcare by developing, producing and marketing affordable generic drugs as well as innovative and specialty pharmaceuticals and active pharmaceutical ingredients.

Teva was established in 1901. Our global headquarters are based in Israel.

Today we have a portfolio of more than 1,000 molecules, producing approximately 64 billion tablets and capsules a year at 66 manufacturing facilities.

We rank among the 10 top pharmaceutical companies in the world and are active in 60 countries. Approximately 58,000 employees around the world are dedicated to our mission.


Trading The News: Teva Pharmaceutical In The News